Last reviewed · How we verify
ENZEEVU (AFLIBERCEPT-ABZV)
ENZEEVU (generic name: AFLIBERCEPT-ABZV) is a drug developed by SANDOZ INC. It is currently FDA-approved.
At a glance
| Generic name | AFLIBERCEPT-ABZV |
|---|---|
| Sponsor | SANDOZ INC |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ENZEEVU CI brief — competitive landscape report
- ENZEEVU updates RSS · CI watch RSS
- SANDOZ INC portfolio CI
Frequently asked questions about ENZEEVU
What is ENZEEVU?
ENZEEVU (AFLIBERCEPT-ABZV) is a pharmaceutical drug developed by SANDOZ INC.
Who makes ENZEEVU?
ENZEEVU is developed and marketed by SANDOZ INC (see full SANDOZ INC pipeline at /company/sandoz).
What is the generic name of ENZEEVU?
AFLIBERCEPT-ABZV is the generic (nonproprietary) name of ENZEEVU.
What development phase is ENZEEVU in?
ENZEEVU is FDA-approved (marketed).
Related
- Manufacturer: SANDOZ INC — full pipeline
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing